Myomo (FRA:0M61) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0M61 Myomo Inc FRA:0M61
59 GF Score
Price €0.95
GF Value €2.58
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myomo Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:0M61
59GF Score
Myomo Inc FRA:0M61
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Myomo (FRA:0M61) Overvalued in 2026?

Based on GuruFocus' analysis, Myomo stock appears to be undervalued. The current stock price of €0.95 is trading 63.2% below its estimated GF Value™ of €2.58. GuruFocus considers Myomo to be Possible Value Trap.

Key valuation signals for FRA:0M61:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €2.58 vs. price of €0.95 (63.2% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the FRA:0M61 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myomo Business Description

Other Exchanges MYO:USA
Address 45 Blue Sky Drive, Suite 101, Burlington, MA, USA, 01803
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
59GF Score

Get the complete analysis for FRA:0M61

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.95
Price
€2.58
GF Value